CRISPR Therapeutics Corp (CRSP) Biznesning o‘zini qoplash muddati

CRISPR (CRSP) brendining ramzi va logotipi

Yuqori R&D xarajatlari va sug'urta to'lovlarini qoplashga oid noaniqliklar tebranishlarni keltirib chiqaradi, bu esa GURU.Markets platformasida CRISPR Therapeutics AG (CRSP) ning joriy P/E koeffitsiyentini kuzatishda, -8.50 belgisi asosiy ko'rsatkich bo'lib xizmat qiladigan narxlar dinamikasida namoyon bo'ladi. CRISPR Therapeutics AG (CRSP) o'zining gen sintezi zavodlari va innovatsiyalarni birgalikda ishlab chiqish uchun global sog'liqni saqlash gigantlari bilan yaqin hamkorliklari orqali barqarorlikni saqlab qolmoqda.

CRSP (crisprtx.com) Narxning foydaga nisbati tarixi 04.07.2022dan 18.11.2026gacha

CRISPR Therapeutics Corp (CRSP) kompaniyasining tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Kompaniyaning jamlanma tahlili:CRISPR Therapeutics - CRSP
CRISPR Therapeutics Inc yetakchi tovari

CRISPR Therapeutics AG (CRSP) kompaniyasining gen terapiyalarini tijoratlashtirishga o'tishi va pul oqimlarining barqarorlashuvi kapital sarfidan operatsion foydaga o'tish uchun asos yaratmoqda. -8.50 qiymatiga ega bo'lgan P/E baholash koeffitsiyentini tahlil qilib, investor biznesning bozor qiymatining uning haqiqiy daromadlariga nisbatini baholaydi, bu esa kelajakdagi o'sish uchun to'langan premium miqdorini aniqlash va aktivning uzoq muddatli barqarorligini baholash imkonini beradi.

Muhim raqobatchilar

tempus.com - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori QGEN|Biznesning o‘zini qoplash muddati Isis Pharmaceuticals|P/E multiplikatori RGEN (repligen.com)|Bozor narxining sof foydaga nisbati RNA (Avidity Biosciences, Inc.)|WGS: Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Ultragenyx (RARE)|BEAM: P/E multiplikatori|Sarepta Therapeutics, Inc. (SRPT) - P/E multiplikatori|TWST (twistbioscience.com) - P/E multiplikatori|10x Genomics, Inc. (TXG) - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti NTLA (Intellia Therapeutics, Inc.)|STOK - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati biolifesolutions.com BLFS|Biznesning o‘zini qoplash muddati Wave Life Sciences Corp (WVE)|MAZE - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati SION (Sionna Therapeutics Inc)|PRME: P/E multiplikatori|Taysha - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati uniQure NV|Narx-foyda multiplikatori MGTX (MeiraGTx PLC)|Narx-foyda koeffitsiyenti RGNX (regenxbio.com)|Solid Biosciences Inc. - Narx-foyda multiplikatori|Narxning foydaga nisbati Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Kapitalizatsiyaning foydaga nisbati|BNTC - Narxning foydaga nisbati|Design Pharma - Bozor narxining sof foydaga nisbati|RCKT (Rocket Pharmaceuticals Inc) - Narx-foyda koeffitsiyenti|4D Molecular Therapeutics (FDMT) - P/E multiplikatori|Narxning foydaga nisbati Lexeo Therapeutics, Inc.|Kapitalizatsiyaning foydaga nisbati Korro Bio, Inc. KRRO|P/E multiplikatori EDIT|Biznesning o‘zini qoplash muddati Silence Therapeutics Corp|Narxning foydaga nisbati proqr.com PRQR|CDXS - Narx-foyda koeffitsiyenti|SGMO - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E multiplikatori|Narx-foyda multiplikatori DTIL|GBIO (Generation Bio) - P/E multiplikatori|Narx-foyda multiplikatori BOLD (boundlessbio.com)|Narx-foyda koeffitsiyenti XCUR (exicuretx.com)|Celsion Corporation - Narx-foyda multiplikatori|P/E multiplikatori PHIO (phiopharma.com)|P/E multiplikatori Mustang Bio, Inc. MBIO|RNAZ: Narx-foyda koeffitsiyenti|BNGO (Bionano Genomics) - Narx-foyda multiplikatori|APDN: P/E multiplikatori|bluebird bio (BLUE) - P/E multiplikatori|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd.|Kapitalizatsiyaning foydaga nisbati Omega OMGA|P/E multiplikatori OMIC|RGLS - Kapitalizatsiyaning foydaga nisbati|Syros Pharmaceuticals, Inc - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Codex DNA (TBIO)|TCON - Narxning foydaga nisbati|UBX: Narxning foydaga nisbati